Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral HP518 in Chinese patients with metastatic castration-resistant prostate cancer
CTR20233691Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HP518 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Dec 2023; status: active.
02
Drugs
HP518
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20233691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233691.